MENINGOCOCCAL DISEASE TREATMENT MARKET ANALYSIS

Meningococcal Disease Treatment MarketSize and Trends

The global meningococcal disease treatment market is estimated to be valued at US$ 3,754.1 million in 2021 and is expected to exhibit a CAGR of 12.6% over the forecast period (2021-2028).

Figure 1. Global Meningococcal Disease Treatment Market Share (%) in Terms of Value, By Region, 2021

Increasing approval of drug is expected to drive the market growth over the forecast period

For instance, in 2018, GlaxoSmithKline Plc., a pharmaceutical company has received breakthrough therapy designation from the U.S. Food and Drug Administration for Bexsero for prevention of invasive meningococcal disease in children 2-10 years of age.

Furthermore, in 2016, Pfizer Inc., a pharmaceutical company, announced that European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for its TRUMENBA (Meningococcal Group B Vaccine) for review.

TRUMENBA is developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older.

Significant number of people travelling to sub-Saharan Africa is expected to propel growth of the global meningococcal disease market

Significant number of people travelling to sub-Saharan Africa is expected to propel growth of the global meningococcal vaccines market over the forecast period. According to World Economic Forum’s, 2018 report, 37.4 million tourist arrivals were recorded in Sub-Saharan Africa in 2017.

Moreover, recommendation of various regulatory bodies for meningococcal vaccination is also expected to aid in growth of the market. For instance, the Centers for Disease Control and Prevention recommends meningococcal vaccines for preteens, teens, and other people.